List of Excipients in Branded Drug EGATEN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	FERRIC OXIDE RED	2026-02-13
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	HYMETELLOSE	2026-02-13
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	LACTOSE MONOHYDRATE	2026-02-13
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	MAGNESIUM STEARATE	2026-02-13
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	SILICON DIOXIDE	2026-02-13
Novartis Pharmaceuticals Corporation	EGATEN	triclabendazole	0078-0937	STARCH, CORN	2026-02-13

EGATEN Excipient Strategy and Commercial Opportunities for Praziquantel

Last updated: October 19, 2026

EGATEN is Novartis’s praziquantel product for schistosomiasis control. Its commercial position depends less on active-ingredient exclusivity than on formulation performance, pediatric usability, supply reliability, and procurement eligibility. The strongest excipient opportunities are taste masking, rapid dispersion, dose flexibility, tropical stability, and low-cost manufacturing.

Praziquantel is an established generic anthelmintic with no material composition-of-matter exclusivity remaining. EGATEN’s defensibility is therefore concentrated in product quality, regulatory documentation, manufacturing know-how, procurement relationships, and pediatric formulation design.

What is EGATEN and which drug substance does it contain?

EGATEN contains praziquantel, a broad-spectrum antischistosomal drug used against infections caused by Schistosoma species. Novartis supplies EGATEN primarily through public-health programs and institutional procurement channels rather than conventional retail markets.

Attribute	EGATEN profile
Active ingredient	Praziquantel
Primary indication	Schistosomiasis
Common adult strength	600 mg tablet
Pediatric development	150 mg dispersible tablet
Manufacturer	Novartis
Primary customers	Governments, international organizations, public-health procurers
Commercial channel	Tender, donation, and institutional supply
Key formulation issue	Very bitter taste and dose fragmentation
Core market constraint	Low-income-country affordability and access

Praziquantel has high public-health value but limited pricing power. The commercial opportunity is tied to large-scale treatment campaigns, pediatric access, and procurement efficiency.

What excipients are used in EGATEN tablets?

Public product information identifies the active ingredient and dosage form, but complete quantitative excipient disclosure is not consistently available across all EGATEN presentations and markets. Publicly described praziquantel tablet formulations commonly use standard direct-compression or granulation excipients such as microcrystalline cellulose, povidone, sodium starch glycolate or another disintegrant, colloidal silicon dioxide, and magnesium stearate.

The exact EGATEN formulation should be confirmed against the applicable country product information, WHO prequalification dossier, or controlled regulatory file before relying on any specific excipient composition.

Likely functional excipient architecture

Excipient function	Relevant formulation objective	Commercial importance
Diluent or filler	Achieve tablet mass and compression performance	High
Binder	Maintain tablet integrity during transport	Medium
Superdisintegrant	Support rapid breakup after administration	High
Lubricant	Enable high-speed tableting and ejection	High
Glidant	Improve powder flow and content uniformity	Medium
Taste-masking agent	Reduce bitterness in pediatric administration	Very high
Sweetener or flavor	Improve acceptability after dispersion	High
Film coat	Improve handling, appearance, and taste barrier	Medium
Moisture-control excipient	Improve tropical stability	High

Praziquantel’s low aqueous solubility and intensely bitter taste make excipient selection commercially significant. A formulation can meet chemical specifications while failing in field use if children reject the dose or caregivers cannot accurately divide the tablet.

Which excipient problems create the largest commercial opportunities?

Taste masking and pediatric acceptability

Praziquantel is highly bitter. Adult tablets can be swallowed whole, but pediatric treatment often requires tablet subdivision or dispersion. Taste masking is therefore the most important excipient opportunity.

Potential approaches include:

• Polymer film coating that limits immediate contact between praziquantel and taste receptors.
• Ion-exchange resin complexes.
• Lipid or solid-dispersion systems.
• Spray-dried taste-masked particles.
• Sweetener and flavor systems compatible with water dispersion.
• Multiparticulate or granule-based pediatric formulations.

The preferred approach must preserve low manufacturing cost, rapid release, and stability under high heat and humidity. A sophisticated taste-masking system that raises tablet cost materially may not be competitive in mass drug administration.

Rapid dispersion and dose flexibility

A pediatric presentation must disperse quickly in a small amount of water and deliver a reproducible dose. Excipients that improve wetting, disintegration, and suspension uniformity can support a differentiated product.

The formulation must address four practical requirements:

1. Dispersion in limited water volumes.
2. Low sedimentation or easy redispersion.
3. Minimal residue in the cup or spoon.
4. Reliable dose delivery when the full dispersion is not consumed immediately.

These requirements create opportunities for co-processed excipients, optimized superdisintegrants, dispersible granules, and low-dose unit presentations.

Tropical stability

Schistosomiasis-endemic regions often have high temperature and humidity. Excipients must support stability during warehouse storage, transport, and field distribution.

Relevant technologies include:

• Low-moisture excipient grades.
• Moisture-barrier film coatings.
• High-barrier blister packaging.
• Desiccant-enabled secondary packaging.
• Improved tablet hardness without delayed disintegration.
• Compatibility screening for cellulose derivatives, superdisintegrants, and lubricants.

Packaging is not an excipient, but the two strategies are linked. A moisture-sensitive formulation may require more expensive packaging, while a robust formulation can reduce total delivered cost.

What formulation patents protect EGATEN or praziquantel products?

Praziquantel itself is an old active ingredient, and basic praziquantel composition-of-matter protection is not a meaningful barrier to generic development. Any current defensibility would more likely arise from:

• Pediatric dispersible compositions.
• Taste-masked particles or coated granules.
• Specific excipient ratios.
• Controlled-release or modified-release formulations.
• Manufacturing processes.
• Combination products.
• New dosing regimens or therapeutic uses.

A patent search should distinguish between patents directed to praziquantel generally and claims that read on the marketed EGATEN dosage form. Broad formulation patents may have limited practical value if they do not cover the actual tablet architecture or if non-infringing alternatives are available.

Patent and exclusivity assessment

Rights category	EGATEN relevance
Praziquantel composition-of-matter patent	No meaningful current barrier expected
Conventional 600 mg tablet	Generally vulnerable to generic competition
Pediatric dispersible tablet	Potential formulation and process protection
Taste-masking technology	Potentially protectable if technically specific
Manufacturing know-how	Important even without enforceable patent rights
Regulatory exclusivity	Depends on jurisdiction and product approval status
Trademark	EGATEN brand remains commercially relevant
Procurement qualification	Can create practical market access advantages

No broad patent conclusion should be drawn from the EGATEN brand name. The key question is whether a specific patent claims a formulation, process, or pediatric presentation that is commercially used and enforceable in the target jurisdiction.

What is the FDA regulatory status of EGATEN?

EGATEN is not the same product as Biltricide, the U.S.-marketed praziquantel product historically associated with Bayer. U.S. regulatory status must be assessed by product and sponsor rather than by active ingredient alone.

The FDA has recognized praziquantel as an established active ingredient, but that does not automatically confer U.S. approval on EGATEN. A company seeking U.S. commercialization would need an applicable FDA approval pathway, which could include an abbreviated new drug application for a pharmaceutically equivalent product or a new drug application for a differentiated pediatric formulation.

WHO prequalification and procurement acceptance can be more commercially important than U.S. approval for EGATEN because the principal market is institutional treatment in endemic countries.

When does EGATEN lose exclusivity?

EGATEN has no single global exclusivity date. Praziquantel is an established generic drug, and any exclusivity depends on the specific product, jurisdiction, formulation, patent, and regulatory pathway.

Exclusivity element	Practical assessment
Active ingredient	Generic and widely available
Standard 600 mg tablet	Low exclusivity barrier
Brand protection	Trademark and market recognition
Pediatric formulation	Possible formulation-specific protection
WHO procurement position	Qualification and supply performance matter
National registration	Country-specific
Data exclusivity	Depends on local regulatory law
Patent expiration	Must be assessed patent by patent

For most competitors, the primary barrier is not patent expiry. It is obtaining acceptable quality, securing registration in endemic markets, meeting procurement specifications, and producing at a price that supports large treatment campaigns.

Which companies are challenging the EGATEN market?

Competition comes from generic praziquantel manufacturers, not necessarily from companies challenging EGATEN through patent litigation. Potential competitors include manufacturers supplying 600 mg tablets to national programs, international donors, and procurement agencies.

The competitive landscape divides into four groups:

1. Established generic manufacturers with low-cost tablet production.
2. Companies developing pediatric dispersible or orally disintegrating presentations.
3. Contract manufacturers offering WHO-compliant production.
4. Excipient and drug-delivery suppliers licensing taste-masking or dispersion technologies.

Generic competition is strongest for standard adult tablets. Pediatric products have greater room for differentiation because taste, dose accuracy, and administration convenience remain unresolved in many settings.

What patent litigation affects EGATEN?

There is no widely reported patent litigation record establishing a major global enforcement campaign around the conventional EGATEN 600 mg praziquantel tablet. Litigation risk is more likely to arise from:

• Disputes over pediatric formulation patents.
• Manufacturing-process claims.
• Trademark or passing-off claims.
• Procurement exclusions.
• Regulatory challenges involving product equivalence.
• Local registration or data-protection disputes.

A Paragraph IV challenge is relevant only in a U.S. ANDA context involving listed patents for the reference product. It is not a general mechanism for challenging EGATEN in endemic-country procurement markets. Publicly available information does not establish a major EGATEN-specific Paragraph IV campaign.

What licensing deals could create commercial value?

Licensing opportunities are more credible around formulation technology than around praziquantel itself. A technology owner could license:

• Taste-masked praziquantel granules.
• Pediatric dispersible tablet platforms.
• Moisture-resistant excipient systems.
• Low-cost coating processes.
• Co-processed excipient blends.
• Continuous manufacturing or high-throughput tableting methods.
• Packaging systems designed for tropical distribution.

A commercially viable agreement would likely require low royalties, volume-based pricing, and rights across multiple endemic countries. A conventional royalty structure based on high-income pharmaceutical pricing would be poorly aligned with public-health procurement economics.

Potential transaction structures include:

Structure	Strategic use
Nonexclusive technology license	Multiple generic suppliers and broad access
Regional license	Country-specific registration and tenders
Supply agreement	Guaranteed excipient or finished-product volumes
Know-how transfer	Local manufacturing and technology access
Milestone-based collaboration	Pediatric formulation development
Cost-plus procurement agreement	Predictable public-health supply

How large is the revenue opportunity for improved EGATEN formulations?

The revenue opportunity is substantial in volume but constrained in unit price. Schistosomiasis control depends on repeated mass treatment of at-risk populations, with children representing a major treatment population. The World Health Organization has identified pediatric praziquantel access as a priority because standard tablets are difficult to administer to young children (World Health Organization, 2023).

Revenue pools are strongest in:

• Pediatric mass drug administration.
• Government tenders.
• Donor-funded procurement.
• WHO-supported programs.
• Country-level registration of dispersible products.
• Local or regional manufacturing partnerships.

A pediatric formulation can command a modest premium if it reduces administration time, improves adherence, lowers wastage, and meets procurement requirements. The addressable commercial value should be modeled by treated doses, tender price, treatment frequency, and eligible population rather than by retail prescription sales.

Novartis’s donation and public-health supply model also limits direct interpretation of conventional pharmaceutical revenue. Publicly reported company revenue does not isolate EGATEN economics in a manner that supports a reliable product-level revenue estimate.

How strong is the EGATEN patent estate?

The estate is likely weak for the conventional praziquantel active ingredient and standard tablet. It may be stronger around pediatric delivery, taste masking, and manufacturing know-how, provided claims are narrow enough to be valid and broad enough to cover commercial alternatives.

Strength factors

• Established active ingredient reduces composition-of-matter protection.
• Standard tablet technology is readily designed around.
• Public-health procurement favors low-cost alternatives.
• Pediatric taste-masking technology can create meaningful differentiation.
• Manufacturing scale and regulatory history may deter smaller entrants.
• WHO qualification can be more valuable than a narrow patent.

Weakness factors

• Many excipients have extensive prior art.
• Simple excipient substitutions are often easy to implement.
• Generic manufacturers can avoid narrow formulation claims.
• Country-by-country enforcement is expensive.
• Donation programs can reduce conventional commercial incentives.

Overall, EGATEN’s practical market position is stronger than its likely basic patent position. Its advantages derive from supply reliability, regulatory documentation, procurement credibility, and field-use experience.

What generic launch risks exist for EGATEN?

A generic manufacturer could launch a conventional praziquantel tablet if it can satisfy local registration, quality, bioequivalence or equivalence requirements, and procurement standards. The principal risks are operational:

• Failure to match dissolution and content uniformity.
• Poor stability in heat and humidity.
• Inadequate tablet scoring or dose subdivision.
• Bitter taste and low pediatric acceptance.
• Inability to meet WHO or national quality requirements.
• Insufficient production capacity during campaign demand.
• Lack of tender eligibility.
• Inadequate pharmacovigilance and supply documentation.

A pediatric generic would face a more complex development program because the formulation must demonstrate not only pharmaceutical equivalence but also practical usability.

How does EGATEN compare with competing praziquantel products?

Criterion	EGATEN 600 mg tablet	Conventional generic 600 mg tablet	Pediatric dispersible product
Active ingredient	Praziquantel	Praziquantel	Praziquantel
Primary user	Older children and adults	Older children and adults	Young children
Taste challenge	High	High	Must be actively managed
Dose flexibility	Limited by tablet splitting	Limited by tablet splitting	High
Procurement relevance	Established	Increasing	Strategic priority
Patent risk	Low for standard tablet	Low	Potentially higher
Manufacturing complexity	Moderate	Moderate	Higher
Commercial differentiation	Brand and supply record	Price	Usability and access
Main barrier	Scale and procurement	Quality and registration	Taste, stability, and cost

The strongest white-space opportunity is a low-cost pediatric product that combines acceptable taste, rapid dispersion, dose accuracy, and tropical stability without materially increasing procurement price.

Key Takeaways

• EGATEN is a praziquantel product whose principal commercial market is institutional schistosomiasis control.
• Standard praziquantel tablets have limited active-ingredient exclusivity and are exposed to generic competition.
• The highest-value excipient opportunity is taste masking for pediatric use.
• Superdisintegrants, dispersibility aids, moisture-control systems, and low-cost coatings are commercially relevant.
• Tropical stability and procurement qualification may matter more than patent ownership.
• Pediatric dispersible formulations offer the clearest differentiation and licensing opportunity.
• FDA approval of a praziquantel product does not establish FDA approval of EGATEN.
• A major EGATEN-specific Paragraph IV or patent litigation campaign is not established by widely available public information.
• Product-level EGATEN revenue cannot be inferred reliably from Novartis’s public financial reporting.
• The strongest competitive strategy is a low-cost, WHO-acceptable pediatric formulation supported by scalable manufacturing and robust regional registration.

FAQs About EGATEN Excipient Strategy and Commercialization

What is the most important excipient for EGATEN pediatric development?

No single excipient determines performance. A combined taste-masking, sweetening, dispersion, and disintegration system is more important than any individual ingredient.

Can a generic manufacturer copy EGATEN’s excipients?

A manufacturer may be able to develop a pharmaceutically equivalent product using different excipients. Exact copying could raise formulation patent, trade-secret, or regulatory issues if protected rights exist in the target country.

Is praziquantel suitable for an orally disintegrating tablet?

It may be technically suitable, but bitterness, dose size, tablet robustness, and manufacturing cost create substantial development constraints. A dispersible tablet or coated granule may be more practical.

Do excipient patents provide strong protection for praziquantel products?

They can provide protection when claims cover a specific taste-masking system, particle architecture, process, or performance parameter. Generic excipient substitutions can weaken the practical scope of narrow claims.

What is the best commercial route for an EGATEN-compatible formulation?

The strongest route is usually institutional procurement through a registered, quality-assured product with pediatric usability, low delivered cost, tropical stability, and manufacturing capacity sufficient for mass-treatment campaigns.

References

1. Novartis. (n.d.). Egaten: Praziquantel product information. Novartis Pharmaceuticals.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/

3. World Health Organization. (2023). WHO guideline for control and elimination of human schistosomiasis. World Health Organization.

4. World Health Organization. (n.d.). Prequalification of medicines and health products. https://extranet.who.int/prequal/

5. World Health Organization. (2019). WHO guideline on control and elimination of human schistosomiasis. World Health Organization.